The efficacy of ganciclovir, given prophylactically, to prevent cytomegalovirus-related disease was evaluated in liver transplant recipients, mostly seropositive, under treatment with OKT3 monoclonal antibodies. The incidence of cytomegalovirus disease and visceral involvement was reduced, respectively, from 52 and 36% in the control group to 12 and 8% in the ganciclovir-treated patients. Leukopenia was a frequent (32%) side effect of ganciclovir administration.
Cytomegalovirus (CMV) is the single most important pathogen in recipients of both solid-organ and bone marrow transplantation (12, 14) . The importance of CMV relies not only in the production of a large variety of clinical syndromes but also in its interaction with the inmune system, which contributes to superinfections and certain forms of organ rejection (6, 11) .
Several strategies attempting to decrease the incidence and severity of CMV disease after organ transplantation have been developed in recent years. The prophylactic administration of ganciclovir (GCV) to seropositive patients has been used successfully to prevent CMV disease in heart transplant recipients (10) . However, the toxicity and cost of a universal prophylaxis have led to a modified approach, termed preemptive therapy, in which GCV is administered only to those patients prone to develop CMV disease (15) . This strategy has been shown to be useful and cost-effective in seropositive bone marrow and kidney transplant recipients (7, 17) .
In CMV-seropositive liver transplant (LT) recipients, the single most important risk factor for developing CMV disease is the use of OKT3 monoclonal antibodies (18, 20) . We have chosen this particular high-risk group of LT recipients to evaluate the efficacy and safety of GCV for the prevention of CMV infection and disease.
From June 1989 to December 1990, 69 adult patients underwent an LT in our hospital and 25 (36%) required the administration of the OKT3 serum for treatment of a steroidresistant rejection. These patients did not receive anti-CMV prophylaxis (neither acyclovir nor immunoglobulin), and they were considered a historical control group (group A). When Active CMV infection was defined by the isolation of the virus from any clinical sample. Symptomatic infection (CMV disease) was diagnosed when CMV was isolated from blood and/or other tissues, accompanied by clinical evidence of CMV infection (e.g., viremia, accompanied by fever with no other cause to account for it, or visceral involvement, such as hepatitis or pneumonitis). CMV hepatitis was diagnosed by the presence of characteristic CMV inclusion bodies or CMV-positive immunofluorescence on a liver biopsy sample together with abnormal liver biochemical tests. CMV pneumonitis was defined by the detection of CMV by histopathological or virological methods from lung biopsy tissue or bronchoalveolar lavage together with radiologic evidence of pneumonitis and a compatible clinical picture. Disseminated CMV disease was defined as tissue involvement of two or more noncontiguous sites. All patients with CMV disease were treated with GCV (5 mg/kg for 14 days). The frequency of CMV excretion did not differ significantly between the groups, but the onset of CMV excretion was apparently delayed in group B patients. This effect may have been due to GCV administration or to more frequent sample collection, off protocol, in group A patients because CMV disease was more frequently suspected. A decrease (77% efficacy) in the incidence of symptomatic infection was noted in the GCV-treated group compared with the incidence in the control group. This decrease was due to the low CMV disease incidence among seropositive recipients receiving GCV prophylaxis (8 versus Leukopenia (total leukocyte count below 3,500/mm3) was the most important side effect related to GCV prophylaxis ( Table 2 ). In two patients, the sustained fall in the leukocyte count necessitated GCV cessation, while a dose reduction was sufficient to control toxicity in the remaining six patients. In all cases, leukopenia appeared after at least 8 days of GCV administration. No significant renal or neurological damage attributable to GCV was observed during the follow-up period.
Although the importance of effective prophylaxis for CMV disease in organ transplant recipients is clear, controversy exists about the most appropriate strategy in the subset of LT patients and particularly in those at highest risk, namely, patients at risk for primary infection and those who require OKT3 therapy. The effect of either conventional or CMV hyperimmune globulin in LT recipients has been quite variable (2, 4, 16) . In a recent randomized, double-blind, placebo-controlled study Snydman et al. (19) administered CMV immune globulin and observed a decrease in the overall incidence and severity of CMV infection and disease in seropositive recipients. However, they found no effect in recipients who were seronegative for CMV and received an organ from a seropositive donor and reported that the use of OKT3 reduced the beneficial effect of CMV immunoglobulin. Stratta et al. found a decrease in the incidence of CMV infections with the combined use of high-dose acyclovir and conventional immunoglobulin in LT recipients at risk of primary infections but not in those receiving OKT3 (20, 21 ). An additional problem of the prophylactic use of CMV immunoglobulin is the high cost of such preparations, which raises the issue of cost-benefit ratio.
The availability of effective antiviral drugs for CMV infection has prompted the evaluation of such agents for the prevention of CMV-related diseases in organ transplant recipients. In contrast with the results of renal transplant studies (1), long-term administration of high-dose acyclovir (800 mg four times daily) does not appear to be effective in preventing CMV infection in LT patients (5, 9) . The combination of GCV administered intravenously in the first 2 weeks after transplant followed by high-dose acyclovir has been reported to be efficacious in seropositive LT recipients (9) . However, the efficacy of the prophylaxis did not extend to seronegative recipients of seropositive allografts, and only a scarce minority of patients included in the study received OKT3. In conclusion, no prophylactic anti-CMV regimen has shown to date a consistent efficacy in reducing the incidence of CMV disease in the high-risk LT population.
Most adult LT recipients in our hospital were CMV seropositive, and our results indicate that GCV clearly reduced the incidence and severity of CMV disease in the subset of these patients requiring antirejection treatment with the OKT3 serum. The very low number of seronegative LT recipients in our study (two patients in group A and one in group B) does not allow us to conclude whether the benefit of prophylaxis also extends to these patients. Although the global mortality was not significantly different in both groups, the severity of CMV disease, measured by the frequency of visceral involvement, was also lowered in the GCV-treated group. This is important in order to avoid the costs and risks of a prolonged hospitalization. The only major side effect in our study was leukopenia, which was detected after at least 1 week of therapy and always with the concurrent administration of another myelotoxic drug (azathioprine). Hibberd et al. (7) administered GCV at a lower dose to kidney transplant recipients, and they did not observe leukopenia as a significant problem, while the efficacy in decreasing the incidence of CMV disease was maintained. Perhaps a lower GCV dosage would be as effective for prophylaxis and less toxic in LT patients receiving OKT3, but this remains to be proved in future clinical trials. Another issue is the possible emergence of GCV-resistant variants of CMV. This has been shown in AIDS patients under prolonged (>3-month) GCV maintenance therapy for CMV retinitis (3). It is unlikely that a short course of prophylaxis would select resistant CMV strains. Indeed, the short duration of the GCV use and its simultaneous administration with the antirejection therapy preclude the need for prolonged hospitalization and avoid the cost and complications of a long ambulatory catheter monitoring.
The fact that this is a nonrandomized trial with historical controls is an important drawback of the study. However, the patient populations were remarkably similar in all factors influencing the development of CMV infection and disease after solid-organ transplantation, and we feel that our results strongly suggest that the prophylactic use of GCV modifies the risk of CMV disease in seropositive LT recipients treated with OKT3 antibodies. These results should be considered as preliminary and might be confirmed in a randomized, placebo-controlled study, although we are aware of the ethical obstacles to undertaking this trial.
